Cargando…

e-Cadherin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson Disease

Today a large number of studies are focused on clarifying the complexity and diversity of the pathogenetic mechanisms inducing Parkinson disease. We used 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a neurotoxin that induces Parkinson disease, to evaluate the change of midbrain structure and...

Descripción completa

Detalles Bibliográficos
Autores principales: Cataldi, Samuela, Codini, Michela, Hunot, Stéphane, Légeron, François-Pierre, Ferri, Ivana, Siccu, Paola, Sidoni, Angelo, Ambesi-Impiombato, Francesco Saverio, Beccari, Tommaso, Curcio, Francesco, Albi, Elisabetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4852763/
https://www.ncbi.nlm.nih.gov/pubmed/27194825
http://dx.doi.org/10.1155/2016/3937057
_version_ 1782429987203186688
author Cataldi, Samuela
Codini, Michela
Hunot, Stéphane
Légeron, François-Pierre
Ferri, Ivana
Siccu, Paola
Sidoni, Angelo
Ambesi-Impiombato, Francesco Saverio
Beccari, Tommaso
Curcio, Francesco
Albi, Elisabetta
author_facet Cataldi, Samuela
Codini, Michela
Hunot, Stéphane
Légeron, François-Pierre
Ferri, Ivana
Siccu, Paola
Sidoni, Angelo
Ambesi-Impiombato, Francesco Saverio
Beccari, Tommaso
Curcio, Francesco
Albi, Elisabetta
author_sort Cataldi, Samuela
collection PubMed
description Today a large number of studies are focused on clarifying the complexity and diversity of the pathogenetic mechanisms inducing Parkinson disease. We used 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a neurotoxin that induces Parkinson disease, to evaluate the change of midbrain structure and the behavior of the anti-inflammatory factor e-cadherin, interleukin-6, tyrosine hydroxylase, phosphatase and tensin homolog, and caveolin-1. The results showed a strong expression of e-cadherin, variation of length and thickness of the heavy neurofilaments, increase of interleukin-6, and reduction of tyrosine hydroxylase known to be expression of dopamine cell loss, reduction of phosphatase and tensin homolog described to impair responses to dopamine, and reduction of caveolin-1 known to be expression of epithelial-mesenchymal transition and fibrosis. The possibility that the overexpression of the e-cadherin might be implicated in the anti-inflammatory reaction to MPTP treatment by influencing the behavior of the other analyzed molecules is discussed.
format Online
Article
Text
id pubmed-4852763
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-48527632016-05-18 e-Cadherin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson Disease Cataldi, Samuela Codini, Michela Hunot, Stéphane Légeron, François-Pierre Ferri, Ivana Siccu, Paola Sidoni, Angelo Ambesi-Impiombato, Francesco Saverio Beccari, Tommaso Curcio, Francesco Albi, Elisabetta Mediators Inflamm Research Article Today a large number of studies are focused on clarifying the complexity and diversity of the pathogenetic mechanisms inducing Parkinson disease. We used 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a neurotoxin that induces Parkinson disease, to evaluate the change of midbrain structure and the behavior of the anti-inflammatory factor e-cadherin, interleukin-6, tyrosine hydroxylase, phosphatase and tensin homolog, and caveolin-1. The results showed a strong expression of e-cadherin, variation of length and thickness of the heavy neurofilaments, increase of interleukin-6, and reduction of tyrosine hydroxylase known to be expression of dopamine cell loss, reduction of phosphatase and tensin homolog described to impair responses to dopamine, and reduction of caveolin-1 known to be expression of epithelial-mesenchymal transition and fibrosis. The possibility that the overexpression of the e-cadherin might be implicated in the anti-inflammatory reaction to MPTP treatment by influencing the behavior of the other analyzed molecules is discussed. Hindawi Publishing Corporation 2016 2016-04-17 /pmc/articles/PMC4852763/ /pubmed/27194825 http://dx.doi.org/10.1155/2016/3937057 Text en Copyright © 2016 Samuela Cataldi et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Cataldi, Samuela
Codini, Michela
Hunot, Stéphane
Légeron, François-Pierre
Ferri, Ivana
Siccu, Paola
Sidoni, Angelo
Ambesi-Impiombato, Francesco Saverio
Beccari, Tommaso
Curcio, Francesco
Albi, Elisabetta
e-Cadherin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson Disease
title e-Cadherin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson Disease
title_full e-Cadherin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson Disease
title_fullStr e-Cadherin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson Disease
title_full_unstemmed e-Cadherin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson Disease
title_short e-Cadherin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson Disease
title_sort e-cadherin in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinson disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4852763/
https://www.ncbi.nlm.nih.gov/pubmed/27194825
http://dx.doi.org/10.1155/2016/3937057
work_keys_str_mv AT cataldisamuela ecadherinin1methyl4phenyl1236tetrahydropyridineinducedparkinsondisease
AT codinimichela ecadherinin1methyl4phenyl1236tetrahydropyridineinducedparkinsondisease
AT hunotstephane ecadherinin1methyl4phenyl1236tetrahydropyridineinducedparkinsondisease
AT legeronfrancoispierre ecadherinin1methyl4phenyl1236tetrahydropyridineinducedparkinsondisease
AT ferriivana ecadherinin1methyl4phenyl1236tetrahydropyridineinducedparkinsondisease
AT siccupaola ecadherinin1methyl4phenyl1236tetrahydropyridineinducedparkinsondisease
AT sidoniangelo ecadherinin1methyl4phenyl1236tetrahydropyridineinducedparkinsondisease
AT ambesiimpiombatofrancescosaverio ecadherinin1methyl4phenyl1236tetrahydropyridineinducedparkinsondisease
AT beccaritommaso ecadherinin1methyl4phenyl1236tetrahydropyridineinducedparkinsondisease
AT curciofrancesco ecadherinin1methyl4phenyl1236tetrahydropyridineinducedparkinsondisease
AT albielisabetta ecadherinin1methyl4phenyl1236tetrahydropyridineinducedparkinsondisease